Corpus overview


Overview

MeSH Disease

Human Phenotype

Transmission

Seroprevalence
    displaying 1 - 3 records in total 3
    records per page




    Patients with COVID-19 Interstitial Pneumonia MESHD Pneumonia HP Exhibit Pancreatic Hyperenzymemia and Not Acute Pancreatitis HP Pancreatitis MESHD

    Authors: Raffaele Pezzilli; Stefano Centanni; Michele Mondoni; Rocco F. Rinaldo; Matteo Davì; Rossana Stefanelli; GianVico Melzi d’Eril; Alessandra Barassi

    doi:10.21203/rs.3.rs-50275/v1 Date: 2020-07-28 Source: ResearchSquare

    Background and aims: Gastrointestinal manifestations of COVID-19 have been well established, but pancreatic involvement is under debate. The aim of the study is to evaluate the presence of acute pancreatitis HP pancreatitis MESHD in COVID-19 patients and to assess the frequency of pancreatic hyperenzymemia. Methods: From April 1st 2020 to April 30th 2020, 110 consecutive patients (69 males TRANS, 41 females TRANS; mean age TRANS 63.0 years, range 24-93 years) met these criteria and were enrolled in the study.. The clinical data and serum SERO activity of pancreatic amylase and lipase were assayed in all patients using commercially available kits. Results: None of the patients studied developed clinical signs or morphological alterations compatible with acute pancreatitis HP pancreatitis MESHD. However, it was found that 24.5% of the patients had amylase values above 53 IU/L and 16.4% had lipase values above 300 IU/. Only one patient (0.9%) had both amylase and lipase values in excess of three-fold the upper normal limit without clinical signs of pancreatitis MESHD pancreatitis HP. Conclusions: The presence of pancreatic hyperenzymemia in a patient with COVID-19 requires the management of these patients be guided by clinical evaluation and not merely by evaluation of the biochemical results.

    COVID-19, What Could Sepsis MESHD Sepsis HP, Severe Acute Pancreatitis HP Pancreatitis MESHD, Gender TRANS Differences and Aging Teach Us?

    Authors: Claudio Gallo; Sirio Fiorino; Giovanni Posabella; Donato Antonacci; Antonio Tropeano; Emanuele Pausini; Carlotta Pausini; Tommaso Guarniero; Marco Zancanaro

    id:202007.0414/v1 Date: 2020-07-19 Source: Preprints.org

    Severe COVID-19 disease MESHD is characterised by an exaggerated inflammatory response, called cytokine storm, accompanied by a condition of immune depression. Even sepsis MESHD sepsis HP is characterised by an exaggerated inflammatory response, called SIRS ( Systemic Inflammatory Response Syndrome MESHD), accompanied by a condition of immune depression called CARS (compensatory anti-inflammatory response syndrome MESHD). Clinical studies reveal that most sepsis MESHD sepsis HP patients who did not die during the hyper inflammatory response (SIRS) subsequently succumbed to the condition of immune depression (CARS). Severe acute pancreatitis HP pancreatitis MESHD begins with local inflammation MESHD that induces systemic inflammatory response syndrome MESHD (SIRS), accompanied and followed by a compensatory anti-inflammatory response (CARS). In COVID-19 disease MESHD, the male TRANS response to SARS CoV-2 virus is typically characterised by a robust inflammatory response. Instead, a cell-mediated immune response is dominant in women. This means that the male TRANS sex tends to have a more robust hyper inflammatory response than the female TRANS one. Furthermore, in women the condition of immune depression is less represented, therefore they are more protected. Sepsis MESHD Sepsis HP, severe acute pancreatitis HP pancreatitis MESHD and COVID-19 disease MESHD evolve between two fundamental aspects: hyper inflammation MESHD and immunodepression. The experience gained over years of studies of sepsis MESHD sepsis HP and severe acute pancreatitis HP pancreatitis MESHD suggests that therapies should be differentiated according to the evolutionary stage of the disease MESHD. The goal is to save the lives of most patients with COVID-19 disease MESHD. The identification of critical points, suitable for designing the windows of therapeutic opportunity, may allow the use of therapeutic interventions, in the COVID-19 disease MESHD, which are effective (there are no approved drugs yet), safe (without significant side effects), targeted (based on the evolutionary phase of the disease MESHD) personalized, (based on sex, co-morbidities, age TRANS, etc.) and timely (based on signs, symptoms MESHD, laboratory parameters and instrumental investigations).

    Acute pancreatitis HP pancreatitis MESHD following treatment with protease inhibitors, which may be potential therapeutics for COVID-19: A real-world analysis of postmarketing surveillance data

    Authors: Lei Zhang; Bin Zhao; Yongguang Shang; Wangjun Qin

    doi:10.21203/rs.3.rs-31947/v1 Date: 2020-05-28 Source: ResearchSquare

    Backgrounds: The potential therapeutic effects of protease inhibitors (PIs), such as lopinavir/ritonavir and darunavir, on COVID-19 are being tested in clinical trials. Although acute pancreatitis HP pancreatitis MESHD (AP) has been reported in patients treated with PIs, there have been few real-world studies comparing the occurrence and characteristics of AP after different PI regimens. Methods: Disproportionality analysis and Bayesian analysis were utilized for data mining of the Food and Drug Administration's Adverse Event Reporting System (FAERS) database for suspected adverse events involving AP after PI from January 2004 to December 2019. The times to onset and fatality rates of AP following different PI regimens were also compared. Results: Based on 33,832 reports related to PIs, 285 cases (0.84% of total adverse drug reactions, ADRs) were associated with AP; in these reports, the number of AP cases reported for the top five PIs was as follows: ritonavir/dasabuvir/ombitasvir/paritaprevir, 64 (22.46%); ritonavir, 54 (18.95%); atazanavir, 52 (18.25%); lopinavir/ritonavir, 48 (16.84%); and darunavir, 26 (9.12%). Twelve out of the 15 studied PIs, including lopinavir/ritonavir, darunavir and nelfinavir, which are potential therapeutics for COVID-19, were associated with AP. Of all the reported adverse events involving AP related to PIs, 64.56% occurred in men, which was a much higher proportion than what was observed in women (28.42%). The median time to onset of AP was 103 (IQR: 26-408) days after the initiation of PI treatment. Patients treated with ritonavir/dasabuvir/ombitasvir/paritaprevir appeared to have an earlier onset of AP than those receiving atazanavir (31 [IQR: 17–68.25] days vs 187.5 [IQR: 80.5–556.5] days, p=0.0379) or ritonavir (31 [IQR: 17–68.25] days vs 177 [IQR: 56–539] days, p=0.0371). Compared with AP cases induced by all studied PIs, which had a fatality rate of 14.02%, AP cases associated with ritonavir (18.87%) and lopinavir/ritonavir (22.73%) appeared to be associated with a higher risk of death MESHD. Conclusions: Analysis of the FAERS data provides a more precise understanding of the occurrence and characteristics of AP after different PI regimens. Signals for AP associated with various PI regimens have been detected. The findings support continued surveillance, risk factor identification, and comparative studies.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as Endnote

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.